The c-Src inhibitor eCF506 diminishes opioid tolerance creating bias against β-arrestin2 recruitment
Samuel Singleton, Fraser Nunn, Erika Lace, Álvaro Lorente‐Macías, Rachel L. Toth, Asier Unciti‐Broceta, Tim G. Hales
The paper tests eCF506, a c-Src inhibitor, showing it reduces opioid tolerance by decreasing β-arrestin2 recruitment without affecting cAMP inhibition.
bioRxiv · Jul 1, 2025 · PreprintNeuroscience